278 related articles for article (PubMed ID: 23038999)
1. Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study.
Peralta G; Lamelo M; Alvarez-García P; Velasco M; Delgado A; Horcajada JP; Montero M; Roiz MP; Fariñas MC; Alonso J; Martínez LM; Gutiérrez-Macías A; Alava JA; Rodríguez A; Fleites A; Navarro V; Sirvent E; Capdevila JA;
BMC Infect Dis; 2012 Oct; 12():245. PubMed ID: 23038999
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
[TBL] [Abstract][Full Text] [Related]
3. [Bacteremia caused by Escherichia coli and Klebsiella pneumoniae producing extended-spectrum betalactamases: mortality and readmission-related factors].
Perianes-Díaz ME; Novo-Veleiro I; Solís-Díaz K; Prolo-Acosta A; García-García I; Alonso-Claudio G
Med Clin (Barc); 2014 May; 142(9):381-6. PubMed ID: 23735867
[TBL] [Abstract][Full Text] [Related]
4. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
[TBL] [Abstract][Full Text] [Related]
6. Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Lo CL; Lee CC; Li CW; Li MC; Hsueh PR; Lee NY; Ko WC
J Microbiol Immunol Infect; 2017 Jun; 50(3):355-361. PubMed ID: 26423244
[TBL] [Abstract][Full Text] [Related]
7. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome.
Kim YK; Pai H; Lee HJ; Park SE; Choi EH; Kim J; Kim JH; Kim EC
Antimicrob Agents Chemother; 2002 May; 46(5):1481-91. PubMed ID: 11959586
[TBL] [Abstract][Full Text] [Related]
8. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years.
Toner L; Papa N; Aliyu SH; Dev H; Lawrentschuk N; Al-Hayek S
World J Urol; 2016 Jul; 34(7):1031-7. PubMed ID: 26511749
[TBL] [Abstract][Full Text] [Related]
9. Propensity-matched analysis of the impact of extended-spectrum β-lactamase production on adults with community-onset Escherichia coli, Klebsiella species, and Proteus mirabilis bacteremia.
Lee CC; Lee CH; Hong MY; Hsieh CC; Tang HJ; Ko WC
J Microbiol Immunol Infect; 2018 Aug; 51(4):519-526. PubMed ID: 28698042
[TBL] [Abstract][Full Text] [Related]
10. Associated factors and clinical outcomes of bloodstream infection due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae during febrile neutropenia.
Ben-Chetrit E; Eldaim MA; Bar-Meir M; Dodin M; Katz DE
Int J Antimicrob Agents; 2019 Apr; 53(4):423-428. PubMed ID: 30572008
[TBL] [Abstract][Full Text] [Related]
11. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
Han SB; Jung SW; Bae EY; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH; Kim HK; Park YJ
Microb Drug Resist; 2015 Apr; 21(2):244-51. PubMed ID: 25398058
[TBL] [Abstract][Full Text] [Related]
12. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
[TBL] [Abstract][Full Text] [Related]
13. Bacteremia Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae in Vientiane, Lao PDR: A 5-Year Study.
Chang K; Rattanavong S; Mayxay M; Keoluangkhot V; Davong V; Vongsouvath M; Luangraj M; Simpson AJH; Newton PN; Dance DAB
Am J Trop Med Hyg; 2020 May; 102(5):1137-1143. PubMed ID: 32157990
[TBL] [Abstract][Full Text] [Related]
14. Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria.
Frakking FN; Rottier WC; Dorigo-Zetsma JW; van Hattem JM; van Hees BC; Kluytmans JA; Lutgens SP; Prins JM; Thijsen SF; Verbon A; Vlaminckx BJ; Cohen Stuart JW; Leverstein-van Hall MA; Bonten MJ
Antimicrob Agents Chemother; 2013 Jul; 57(7):3092-9. PubMed ID: 23612198
[TBL] [Abstract][Full Text] [Related]
15. An observational study on bloodstream extended-spectrum beta-lactamase infection in critical care unit: incidence, risk factors and its impact on outcome.
Nasa P; Juneja D; Singh O; Dang R; Singh A
Eur J Intern Med; 2012 Mar; 23(2):192-5. PubMed ID: 22284253
[TBL] [Abstract][Full Text] [Related]
16. Bacteremic pneumonia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Appropriateness of empirical treatment matters.
Cheng WL; Hsueh PR; Lee CC; Li CW; Li MJ; Chang CM; Lee NY; Ko WC
J Microbiol Immunol Infect; 2016 Apr; 49(2):208-15. PubMed ID: 25070279
[TBL] [Abstract][Full Text] [Related]
17. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
[TBL] [Abstract][Full Text] [Related]
18. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia.
Martínez JA; Aguilar J; Almela M; Marco F; Soriano A; López F; Balasso V; Pozo L; Mensa J
J Antimicrob Chemother; 2006 Nov; 58(5):1082-5. PubMed ID: 16950822
[TBL] [Abstract][Full Text] [Related]
19. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program.
Bhavnani SM; Ambrose PG; Craig WA; Dudley MN; Jones RN;
Diagn Microbiol Infect Dis; 2006 Mar; 54(3):231-6. PubMed ID: 16423491
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.
Chopra T; Marchaim D; Johnson PC; Chalana IK; Tamam Z; Mohammed M; Alkatib S; Tansek R; Chaudhry K; Zhao JJ; Pogue JM; Kaye KS
Am J Infect Control; 2015 Jul; 43(7):719-23. PubMed ID: 25934068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]